2 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow Plasma Cell Disorder: new trials by email Literature Review of Plasma Cell Disorder trials Research Report on Plasma Cell Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders Daratumumab Injection - Plasma Cell Disorder | Phase 1 / Phase 2 | Recruiting | University of Maryland, Baltimore | 30 | 2025-10-23 | 2026-10-29 |
| Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma HDP-101 - Multiple Myeloma, Plasma Cell Disorder | Phase 1 / Phase 2 | Recruiting | Heidelberg Pharma AG | 78 | 2022-02-07 | 2026-09-17 |
Neoplasms, Plasma Cell (2) · Multiple Myeloma (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Paraproteinemias (1) · Vascular Diseases (1)
daratumumab (1)
Heidelberg Pharma AG (1) · University of Maryland, Baltimore (1)
United States (2) · Germany (1) · Hungary (1) · Poland (1) · Romania (1)